F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis.
Acta Radiol
; 57(10): 1193-200, 2016 Oct.
Article
en En
| MEDLINE
| ID: mdl-26163534
ABSTRACT
BACKGROUND:
Positron emission tomography (PET) with fluor-18-deoxy-glucose (FDG) is widely used for diagnosing recurrent or metastatic disease in patients with differentiated thyroid cancer (DTC).PURPOSE:
To assess the diagnostic accuracy of FDG-PET for DTC in patients after ablative therapy. MATERIAL ANDMETHODS:
A systematic search was conducted in Medline/PubMed, EMBASE, Cochrane Library, Web of Science, and Open Grey looking for all English-language original articles on the performance of FDG-PET in series of at least 20 patients with DTC having undergone ablative therapy including total thyroidectomy. Diagnostic performance measures were pooled using Reitsma's bivariate model.RESULTS:
Thirty-four publications between 1996 and 2014 met the inclusion criteria. Pooled sensitivity and specificity were 79.4% (95% confidence interval [CI], 73.9-84.1) and 79.4% (95% CI, 71.2-85.4), respectively, with an area under the curve of 0.858.CONCLUSION:
F18-FDG-PET is a useful method for detecting recurrent DTC in patients having undergone ablative therapy.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias de la Tiroides
/
Radiofármacos
/
Fluorodesoxiglucosa F18
/
Tomografía de Emisión de Positrones
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Prognostic_studies
/
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
Acta Radiol
Año:
2016
Tipo del documento:
Article
País de afiliación:
Noruega